From pipeline email:

Chelsea Therapeutics Announces Interim Results and Plans to Modify Study 306 to Focus on Reduction in Falls Associated With Neurogenic Orthostatic Hypotension

Parkinson’s Disease Patients Treated With Northera Demonstrate 60% Decrease in Falls

"Parkinson’s disease (PD) is the second most common neurodegenerative disorder in America. As a result of decreased levels of norepinephrine associated with PD, approximately 20% of PD patients may experience symptomatic NOH. NOH is a neurogenic disorder resulting from deficient release of norepinephrine, the neurotransmitter used by sympathetic autonomic nerves to send signals to the blood vessels and the heart to regulate blood pressure. This deficiency results in decreased blood pressure when a person assumes a standing position and is characterized by lightheadedness, dizziness, and falls. Symptoms of chronic NOH can be incapacitating, not only putting patients at high risk for falls and generating significant health care costs, but also severely affecting the quality of life for patients and their loved ones."

http://www.iewy.com/16279-chelsea-th...potension.html